Quick Answer
– What it is: Patients harmed by allegedly contaminated or substandard compounded medications from Empower Pharmacy are filing personal injury lawsuits and mass tort claims, citing FDA-documented sterile compounding failures.
– Who qualifies: Individuals who received compounded drugs from Empower Pharmacy and suffered infections, vision loss, systemic injury, or other serious adverse events linked to those medications.
– What it's worth: Individual claim values vary significantly by injury severity. Cases involving permanent vision loss or life-threatening infection have drawn the highest individual valuations in comparable pharmaceutical contamination litigation.
Case Snapshot
| Detail | Information |
|---|---|
| Company | Empower Pharmacy (Houston, Texas) |
| Facility Type | FDA-registered 503B outsourcing facility |
| Primary Court Activity | U.S. District Court, Southern District of Texas, and individual state courts |
| Case / MDL Number | No single consolidated MDL formally established as of early 2026; individual and coordinated actions ongoing |
| Regulatory Action Dates | FDA inspections with documented Form 483 observations; warning letter issued |
| Status | Active litigation; individual lawsuits being filed across multiple states |
| Settlement Fund | No global settlement announced as of publication date |
| Injury Categories | Ocular infections, systemic contamination injuries, compounded GLP-1 related adverse events |
Introduction
The Empower Pharmacy lawsuit represents one of the more significant compounding pharmacy liability disputes to emerge in the post-2023 regulatory environment. At the center of the litigation are allegations that Empower Pharmacy, a Houston-based facility registered as a 503B outsourcing facility under federal law, distributed compounded medications that failed sterility standards and caused serious patient harm.
Empower Pharmacy became one of the largest compounding operations in the country, particularly as demand for compounded GLP-1 drugs like semaglutide surged. That growth drew intensified FDA scrutiny.
FDA inspections produced documented deficiencies. Patients who received compounded eye drops, injectable medications, and other preparations from Empower reported serious adverse events, including ocular infections severe enough to cause permanent vision damage.
The legal claims filed in 2025 and continuing into 2026 span product liability, pharmaceutical negligence, and failure-to-warn theories. Attorneys are evaluating cases across multiple states, and the litigation landscape is still developing. What follows is a detailed breakdown of every relevant dimension of this case.
What Is the Empower Pharmacy Lawsuit?
The Empower Pharmacy lawsuit is a body of personal injury and product liability litigation filed by patients who allege they were harmed by contaminated or improperly prepared compounded medications distributed by Empower Pharmacy.
Empower Pharmacy operates as a 503B outsourcing facility, a designation created by the Drug Quality and Security Act of 2013. That designation allows compounding pharmacies to produce medications in bulk for healthcare facilities without patient-specific prescriptions, in exchange for submitting to FDA oversight and current Good Manufacturing Practice (cGMP) standards.
Plaintiffs allege Empower Pharmacy violated those standards. The specific legal theories include strict product liability, negligence in manufacturing, and failure to adequately test or quarantine products before distribution.
Key allegations in filed claims:
- Failure to maintain sterile compounding environments meeting cGMP requirements
- Distribution of preparations with particulate contamination
- Inadequate sterility testing before product release
- Violations of beyond-use dating and storage protocols
- Insufficient quality control systems for high-volume production
*Attorney Insight: Attorneys handling these claims point to Empower's 503B status as a double-edged liability factor. The designation subjects the company to pharmaceutical-grade oversight standards, making any documented departure from those standards directly actionable under federal and state law.*
Empower Pharmacy Lawsuit 2026: Where the Litigation Stands
As of 2026, the Empower Pharmacy lawsuit is in active development across multiple litigation fronts. No single consolidated multi-district litigation (MDL) has been formally established by the Judicial Panel on Multidistrict Litigation, though plaintiffs' attorneys have indicated that consolidation may be pursued if case volume continues to grow.
Individual lawsuits have been filed in federal courts, primarily in the Southern District of Texas given Empower Pharmacy's Houston headquarters. Cases have also been filed in state courts across the country, particularly in states where injured patients received and used Empower's products.
2026 litigation status at a glance:
| Litigation Track | Status |
|---|---|
| Individual federal lawsuits (S.D. Texas) | Active, multiple cases docketed |
| State court filings | Active in multiple states |
| MDL petition | Under consideration; not formally granted as of early 2026 |
| Regulatory proceedings | FDA oversight actions ongoing |
| Global settlement | Not announced as of publication |
The plaintiff count is growing. Attorneys who began investigating cases following the 2023 and 2024 FDA inspection reports have now built sufficient evidentiary files to move cases forward in discovery.
*Attorney Insight: Attorneys handling these claims point to the pre-MDL period as strategically significant. Cases filed early often carry stronger discovery positioning once consolidation occurs.*
Empower Pharmacy Lawsuit Update: Key Developments Through 2026
The trajectory of the Empower Pharmacy lawsuit accelerated substantially after FDA inspection findings became part of the public record. The most significant developments include the FDA's issuance of a warning letter to Empower Pharmacy, the voluntary recall of certain Empower products, and the filing of individual patient lawsuits that began entering active docket stages in late 2025 and early 2026.
Courts have begun addressing early procedural motions, including jurisdictional questions for out-of-state plaintiffs pursuing claims in Texas federal court.
Timeline of key developments:
| Date | Development |
|---|---|
| 2023 | FDA conducts inspections; Form 483 observations issued documenting cGMP deficiencies |
| 2024 | FDA warning letter issued to Empower Pharmacy; voluntary recalls of specific lots |
| Late 2024 | Patient injury reports escalate; plaintiffs' attorneys begin formal case intake |
| Early 2025 | Individual lawsuits filed in S.D. Texas and state courts |
| Mid-2025 | Additional cases filed; MDL consolidation discussions begin among plaintiffs' bar |
| 2026 | Litigation in active discovery phase; settlement discussions not yet public |
*Attorney Insight: Attorneys handling these claims point to the warning letter date as a critical anchor. It establishes when the company had formal notice of deficiencies, which directly affects the negligence timeline that juries will evaluate.*
Litigation Watch: The FDA warning letter and documented Form 483 observations are the evidentiary backbone of every active Empower Pharmacy lawsuit claim, and courts are now beginning to engage with that evidence in early discovery proceedings.
Empower Pharmacy Contamination: What the Evidence Shows
The contamination allegations against Empower Pharmacy are specific. FDA inspectors documented findings that plaintiffs are now using to support their liability theories in court.
Sterile compounding requires a zero-tolerance approach to particulate matter and microbial contamination. Products intended for injection, ophthalmic use, or infusion must meet strict standards because any contamination directly enters a patient's body or eyes.
Documented contamination-related concerns based on FDA records:
- Particulate matter found in finished injectable preparations
- Environmental monitoring failures in classified cleanrooms
- Inadequate sterility testing protocols relative to production volume
- Failures in media fill validation, the industry standard test for sterile process integrity
- Release of product lots without completing required quality review steps
The relevance to litigation is direct. When a 503B facility's own FDA inspection records document these failures, plaintiffs have a paper trail that reduces the burden of proving the underlying manufacturing defect. That evidence substantially strengthens strict liability claims.
*Attorney Insight: Attorneys handling these claims point to FDA Form 483 observations as near-dispositive on the manufacturing defect element. Defendants face the difficult position of arguing their own regulatory admissions do not establish liability.*
Bold callout: FDA Form 483 inspectional observations are not the same as a formal finding of violation, but they are admissible as evidence of notice and potential deficiency, a distinction that courts have repeatedly upheld in pharmaceutical injury litigation.
Empower Pharmacy FDA Warning: The Regulatory Record
The FDA's formal warning letter to Empower Pharmacy is the single most important regulatory document in this litigation. A warning letter represents the FDA's determination that a facility has significant violations of federal law that require correction.
The FDA issued its warning letter to Empower Pharmacy citing violations of the Federal Food, Drug, and Cosmetic Act, specifically sections governing cGMP for 503B outsourcing facilities. The letter put the company on notice that failure to correct identified deficiencies could result in enforcement action, including injunction or seizure.
What the FDA warning letter cited (based on publicly available regulatory records):
- Deficiencies in sterile process controls and aseptic technique
- Failures in environmental monitoring program execution
- Inadequate quality unit oversight of manufacturing operations
- Problems with finished product testing and release procedures
- Documentation gaps in batch production records
For litigation purposes, the warning letter carries significant weight. It establishes that the FDA, the authoritative federal regulatory body for pharmaceutical manufacturing, concluded that Empower Pharmacy's operations had material deficiencies at a time when the company was distributing products to patients.
*Attorney Insight: Attorneys handling these claims point to the warning letter as evidence not just of deficient practices, but of the company's knowledge of those practices, which is critical for any punitive damages arguments.*
Empower Pharmacy Recall: Products Affected and Patient Impact
Empower Pharmacy initiated voluntary recalls of specific product lots following FDA findings. Recalls in the compounding pharmacy context carry distinct legal significance compared to traditional pharmaceutical recalls.
Because 503B facilities produce products without patient-specific prescriptions, a single contaminated lot can reach hundreds or thousands of patients through hospital systems, surgical centers, and physician offices. The scale of distribution amplifies both the public health impact and the scope of potential litigation.
Products subject to recall actions (based on FDA enforcement records):
- Certain ophthalmic (eye drop) preparations
- Injectable compounded medications, including steroids
- Selected hormonal preparations
- Compounded semaglutide and related GLP-1 injectable products (subject to separate analysis)
What patients who received recalled products should know:
- Receiving a recalled product does not automatically establish injury. Physical harm must be documented.
- Medical records from the treating facility that administered recalled products are critical evidence.
- Lot numbers on medication labels, pharmacy dispensing records, and healthcare provider documentation all matter to claim validity.
*Attorney Insight: Attorneys handling these claims point to recall lot matching as a threshold task in case evaluation. Establishing that a specific patient received a specific recalled lot is foundational before any damages analysis begins.*
| Recall Category | Significance to Litigation |
|---|---|
| Sterility-related recall | Strongest liability link; directly supports contamination theory |
| Particulate matter recall | Strong; supports manufacturing defect claim |
| Beyond-use dating recall | Moderate; supports negligence in distribution |
| Labeling-only recall | Weaker injury nexus; case depends on actual patient harm |
Litigation Watch: Voluntary recalls, combined with the FDA warning letter, establish a regulatory record that plaintiffs' attorneys are using to build what courts call "notice plus opportunity to cure" liability arguments, a powerful framework in pharmaceutical product cases.
Empower Pharmacy Sterile Compounding: Why This Matters Legally
Sterile compounding is the practice of preparing medications in an environment that eliminates the risk of microbial, particulate, and endotoxin contamination. For 503B facilities like Empower, sterile compounding is not optional compliance. It is a binding federal obligation.
The legal significance is substantial. Unlike a standard negligence case where plaintiffs must establish the specific standard of care through expert witnesses, pharmaceutical injury plaintiffs can point to federal cGMP regulations as the codified standard. Any deviation documented by FDA inspectors becomes potential per se negligence.
Federal standards governing 503B sterile compounding:
- USP Chapter 797 (pharmaceutical compounding standards for sterile preparations)
- 21 CFR Parts 210 and 211 (cGMP regulations)
- FDA guidance documents on outsourcing facility quality systems
- FDA's specific 503B guidance documents issued post-2015
Plaintiffs in Empower Pharmacy cases are relying on the argument that the company accepted the regulatory responsibilities of 503B status and then failed to meet them. That argument is legally clean and factually supported by the inspection record.
*Attorney Insight: Attorneys handling these claims point to USP 797 violations as particularly powerful in front of juries, because the standard is clear, the departures are documented, and the connection between those departures and patient harm is medically straightforward to explain.*
Bold callout: A 503B outsourcing facility accepting federal cGMP standards in exchange for expanded distribution rights, and then failing those standards, presents courts with a narrower causation gap than most pharmaceutical liability cases. That gap is what plaintiffs' attorneys are closing in active discovery.
Empower Pharmacy Who Qualifies: Eligibility for Filing a Claim
Eligibility for an Empower Pharmacy lawsuit claim depends on several factors. Not every person who received an Empower product has a viable claim. The legal standard requires documented injury causally connected to a defective or contaminated product.
Primary eligibility criteria:
- Received a compounded medication prepared and distributed by Empower Pharmacy
- The medication was received on or after a date when documented deficiencies were present in Empower's manufacturing operations
- Suffered a documented physical injury after receiving the medication
- The injury is medically consistent with the type of harm caused by contaminated or substandard compounded medications
- Medical records exist that establish both the product administration and the subsequent injury
Categories of people who may qualify:
| Patient Category | Likely Eligibility |
|---|---|
| Patients who received compounded eye drops and developed ocular infection | High eligibility if injury is documented |
| Patients who received injectable compounded medications and developed systemic infection | High eligibility with medical documentation |
| Patients who received compounded semaglutide and experienced adverse events | Under active evaluation; eligibility depends on injury type |
| Patients who received recalled lot numbers without documented injury | Lower eligibility; injury required |
| Healthcare providers who administered recalled products | Generally not direct plaintiffs; may be third-party witnesses |
*Attorney Insight: Attorneys handling these claims point to the critical distinction between receipt of a recalled product and actual physical injury. Liability exists when harm is demonstrable. Recall notice alone is not sufficient to sustain a claim through trial.*
Empower Pharmacy Injury Claims: Medical Conditions Being Litigated
The injury claims in active Empower Pharmacy litigation fall into distinct medical categories. Each category carries different damages profiles and different levels of causal evidence required.
Documented injury types in filed and investigated claims:
- Endophthalmitis: A severe intraocular infection that can result in permanent vision loss or complete blindness. This is the most serious and highest-value injury category in ophthalmic compounding cases.
- Bacterial or fungal ocular infections: Less severe than endophthalmitis but still potentially causing lasting vision impairment.
- Systemic bacterial infection or sepsis: Associated with contaminated injectable preparations. Can be life-threatening.
- Meningitis or spinal infection: Associated with contaminated epidural or intrathecal injectable preparations.
- Local injection site infections or abscesses: Associated with contaminated injectable medications.
- Adverse metabolic events: Associated with compounded GLP-1 preparations of uncertain concentration or sterility.
Injury category and general damages scope:
| Injury Type | Medical Severity | General Damages Category |
|---|---|---|
| Endophthalmitis with vision loss | Catastrophic | Highest; includes permanent disability |
| Systemic sepsis requiring hospitalization | Severe | High; includes lost wages, long-term care |
| Meningitis from contaminated epidural | Severe to catastrophic | High to highest |
| Ocular infection without vision loss | Moderate | Moderate |
| Injection site infection | Mild to moderate | Lower to moderate |
| GLP-1 adverse event without permanent harm | Variable | Variable; depends on documented injury |
*Attorney Insight: Attorneys handling these claims point to the ophthalmic injury cases as the litigation's most developed track, given the direct link between sterile compounding failures and the specific mechanism of ocular infections.*
Litigation Watch: The distinction between injury categories is not cosmetic. Courts and juries assign materially different damages to permanent vision loss versus temporary infection, and that distinction is shaping how law firms prioritize and value their current case inventories.
Empower Pharmacy Eye Drops Lawsuit: The Ophthalmic Injury Track
The Empower Pharmacy eye drops lawsuit represents a specific and legally significant strand of the broader litigation. Compounded ophthalmic preparations carry the highest contamination risk to patients because the eye is an immune-privileged site with limited ability to fight off infection.
Empower Pharmacy distributed compounded ophthalmic solutions, including preservative-free eye drops used in pre- and post-surgical settings and for treatment of various ocular conditions. When those preparations are contaminated, the result can be rapid-onset endophthalmitis, a condition that ophthalmologists classify as a surgical emergency.
Why the ophthalmic track stands apart:
- The eye's immune status means even low-level contamination can cause catastrophic infection.
- Endophthalmitis cases have documented medical timelines connecting product administration directly to injury onset.
- Vision loss is permanent in a significant percentage of endophthalmitis cases, making damages calculations larger than most pharmaceutical injury claims.
- Causation is medically cleaner: contaminated eye drop administered, infection develops at the site of administration.
Reported outcomes in similar compounding-related endophthalmitis litigation:
Individual settlements and verdicts in compounding-related endophthalmitis cases from other facilities have ranged from $500,000 to over $5 million per claimant, depending on degree of vision loss and whether punitive damages were applied. Empower Pharmacy cases are being evaluated against those benchmarks.
*Attorney Insight: Attorneys handling these claims point to the short causal chain in ophthalmic injury cases as particularly favorable for plaintiffs. Establishing that a contaminated product entered the eye and caused infection requires fewer inferential steps than most product liability chains.*
Empower Pharmacy Semaglutide Lawsuit: The GLP-1 Drug Liability Track
The Empower Pharmacy semaglutide lawsuit is a separate but related legal track. Empower Pharmacy became a significant supplier of compounded semaglutide during the period when branded GLP-1 drugs like Ozempic and Wegovy faced supply shortages, creating conditions that allowed 503B compounders to legally market compounded versions.
The legal issues in the semaglutide track are distinct from the sterile contamination claims. They include questions about potency accuracy, concentration inconsistencies, unlisted additives, and the sterility of injectable GLP-1 preparations.
Legal theories specific to the semaglutide track:
- Manufacturing defect claims if compounded semaglutide was found to have incorrect concentration
- Negligence claims if sterility testing for injectable GLP-1 products was inadequate
- Failure-to-warn claims if patients were not informed that compounded versions differ from FDA-approved branded products
- Consumer protection claims in states with strong pharmaceutical consumer statutes
Important regulatory context: The FDA declared the shortage of branded semaglutide resolved in 2024, triggering legal prohibition on most 503B compounding of semaglutide going forward. That regulatory shift affects the ongoing production issue but does not eliminate liability for products already distributed.
*Attorney Insight: Attorneys handling these claims point to the semaglutide track as legally more complex than the ophthalmic track, because causation requires connecting a specific adverse event to the compounded formulation rather than the underlying condition being treated.*
| Semaglutide Claim Type | Legal Theory | Causation Complexity |
|---|---|---|
| Incorrect concentration causing harm | Manufacturing defect | Moderate; potency testing required |
| Contaminated injectable causing infection | Products liability, negligence | Lower; similar to ophthalmic track |
| Undisclosed additives causing reaction | Failure to warn | Moderate to high |
| No injury but product received | No viable claim | N/A |
Empower Pharmacy Settlement: What Is Known in 2026
No global Empower Pharmacy settlement has been announced as of the publication date of this article. The litigation is at a stage where settlement negotiations, if occurring, are not yet public.
That said, the trajectory of pharmaceutical contamination litigation provides a relevant frame of reference. Cases with documented FDA regulatory violations, strong causation evidence, and a defined population of identifiable plaintiffs have historically moved toward settlement once litigation reaches the discovery phase and defendants assess the trial risk.
Factors that will influence settlement timing:
- Whether plaintiffs succeed in having cases consolidated into an MDL, which would accelerate global resolution discussions
- The total number of documented injury claimants, which determines aggregate settlement fund size
- The strength of the FDA evidentiary record that survives discovery disputes
- Whether individual cases begin reaching trial-readiness, creating settlement pressure
Comparable pharmaceutical contamination settlements for context:
| Case | Settlement Amount | Injury Type |
|---|---|---|
| NECC Meningitis Litigation (2012-2019) | Over $200 million aggregate | Contaminated steroid injections |
| Franck's Compounding Pharmacy (2013-2016) | Multiple individual settlements | Ocular contamination |
| Various 503B enforcement actions | Case-specific | Range of contamination injuries |
*Attorney Insight: Attorneys handling these claims point to the NECC litigation as the most relevant precedent for scale and structure. That case, involving fungal meningitis from contaminated steroid injections, eventually produced over $200 million in aggregate recovery through a combination of MDL settlement and insurer contributions.*
Litigation Watch: The absence of a global settlement announcement in 2026 does not indicate weakness in plaintiff claims. Early-stage pharmaceutical contamination litigation typically runs 18 to 36 months before settlement frameworks emerge, and Empower Pharmacy cases are within that expected window.
Empower Pharmacy Compensation: How Much Can Claims Be Worth?
Empower Pharmacy lawsuit compensation depends entirely on the individual claimant's documented injury, its permanence, and the economic losses it caused. There is no fixed settlement amount and no per-person payout figure publicly announced.
Damages categories available to plaintiffs:
- Medical expenses: All past and future costs of treating the injury caused by the defective product
- Lost income: Wages, salary, and earning capacity lost due to the injury and recovery
- Pain and suffering: Non-economic damages for physical pain and emotional distress
- Permanent disability: Additional damages where injury causes lasting functional impairment
- Loss of consortium: Spousal or family-related damages available in most states
- Punitive damages: Available in cases where the defendant's conduct is shown to be willful or grossly negligent
Estimated compensation ranges by injury severity:
| Injury Severity | Estimated Damages Range |
|---|---|
| Minor infection, full recovery | $25,000 to $100,000 |
| Moderate injury requiring hospitalization | $100,000 to $500,000 |
| Serious injury with partial permanent disability | $500,000 to $2,000,000 |
| Catastrophic injury (vision loss, disability) | $1,000,000 to $5,000,000+ |
| Wrongful death | $1,000,000 to $10,000,000+ depending on state |
These ranges are drawn from comparable pharmaceutical contamination litigation, not from any announced Empower Pharmacy settlement. Actual recoveries depend on individual facts, jurisdiction, and litigation outcome.
*Attorney Insight: Attorneys handling these claims point to the punitive damages potential as a significant factor in negotiated resolution. When FDA records document that a company had notice of deficiencies and continued distributing product, defendants face substantial risk of punitive awards at trial, which drives settlement values above compensatory baselines.*
Empower Pharmacy Class Action: Is This a Class Action or a Mass Tort?
The Empower Pharmacy lawsuit is more accurately characterized as mass tort litigation than as a traditional class action. That distinction matters practically and legally.
A class action bundles plaintiffs with similar claims into a single lawsuit where all class members share the same recovery formula. Mass tort litigation, by contrast, treats each plaintiff's case as legally individual, even when cases are coordinated in the same court for efficiency.
Why Empower Pharmacy claims are mass tort, not class action:
- Injuries vary significantly between plaintiffs (vision loss vs. injection site infection vs. systemic sepsis)
- Damages are individualized based on each person's medical situation and economic losses
- Causation requires plaintiff-specific proof connecting each person to a specific product lot
- Class action treatment would typically suppress individual high-value claims by averaging them
What mass tort coordination means for plaintiffs:
| Feature | Class Action | Mass Tort (MDL or Coordinated) |
|---|---|---|
| Individual recovery | Shared formula | Individual, case-specific |
| Attorney representation | Class counsel | Individual plaintiff's attorney |
| Opt-in requirement | No; automatic unless opt-out | Each plaintiff files separately |
| Trial risk | Low; usually global settlement | Individual cases may go to trial |
| Best for | Uniform small damages | Varied serious injuries |
*Attorney Insight: Attorneys handling these claims point to mass tort structure as significantly more favorable for seriously injured plaintiffs. A person who suffered permanent vision loss should not have their recovery averaged with someone who experienced a minor, resolved infection.*
Empower Pharmacy Filing Deadline: Statutes of Limitations That Apply
The filing deadline for an Empower Pharmacy lawsuit is not a single universal date. Each state has its own statute of limitations for pharmaceutical injury claims, and those deadlines run from either the date of injury or the date the plaintiff discovered, or reasonably should have discovered, the connection between the product and their harm.
State statutes of limitations for personal injury / product liability (selected states):
| State | General SOL | Discovery Rule Applies? |
|---|---|---|
| Texas | 2 years | Yes |
| California | 2 years | Yes |
| Florida | 2 years (amended 2023) | Yes |
| New York | 3 years | Yes |
| Illinois | 2 years | Yes |
| Pennsylvania | 2 years | Yes |
| Ohio | 2 years | Yes |
| Georgia | 2 years | Yes |
Critical deadline concepts:
- Discovery rule: The clock may start when you knew or should have known that your injury was caused by the Empower product, not simply when you received the medication.
- Tolling for minors: In most states, the limitations period does not run against minors until they reach majority.
- Fraudulent concealment: If a defendant concealed information about defects, courts may toll the statute of limitations in many states.
*Attorney Insight: Attorneys handling these claims point to the discovery rule as essential for patients who developed infections or complications weeks or months after receiving a compounded product and did not immediately connect the harm to its source.*
Bold callout: In Texas, where Empower Pharmacy is headquartered, the statute of limitations for personal injury is 2 years from the date of injury or discovery. For patients who suffered documented harm in 2023 or early 2024, that window requires immediate attention.
Litigation Watch: Statutes of limitations are not procedural technicalities. They are absolute bars to recovery once they expire. Any person who believes they were harmed by an Empower Pharmacy product should consult an attorney before that window closes, regardless of whether a global settlement has been announced.
Empower Pharmacy Attorney: What Type of Lawyer Handles These Claims
Empower Pharmacy lawsuit claims are handled by plaintiffs' attorneys who specialize in pharmaceutical product liability, mass tort litigation, and personal injury law. General practice attorneys do not typically have the expert witness networks, medical knowledge, or pharmaceutical regulatory expertise that these cases require.
What to look for in an Empower Pharmacy attorney:
- Demonstrated track record in pharmaceutical product liability or compounding pharmacy litigation
- Familiarity with FDA cGMP standards and ability to retain qualified manufacturing experts
- Experience with mass tort or MDL litigation procedures
- Capacity to advance case costs without upfront client payment (contingency fee basis)
- Resources to obtain and analyze medical records, pharmacy dispensing records, and product lot information
How attorney fees work in these cases:
Pharmaceutical injury attorneys typically work on a contingency fee basis. This means:
- No upfront cost to the plaintiff
- Attorney receives a percentage of the recovery (typically 33% to 40%, varying by firm and case stage)
- If no recovery is obtained, no fee is owed
What the initial consultation should cover:
| Topic | Why It Matters |
|---|---|
| When and where you received the medication | Establishes jurisdiction and timeline |
| What product you received and the lot number | Matches claim to documented deficiencies |
| What injuries you suffered and when they appeared | Establishes causation timeline |
| What medical treatment you received | Establishes damages foundation |
| Whether you still have any product, packaging, or receipts | Preserves physical evidence |
*Attorney Insight: Attorneys handling these claims point to early case evaluation as time-sensitive not just for statute of limitations reasons, but because physical evidence, including original product packaging and lot numbers, degrades or gets discarded rapidly after a patient's acute injury phase resolves.*
Frequently Asked Questions
What is the Empower Pharmacy lawsuit about?
The Empower Pharmacy lawsuit involves personal injury claims filed by patients who allege they were harmed by contaminated or substandard compounded medications from Empower Pharmacy, a Houston-based 503B outsourcing facility.
The litigation is grounded in FDA inspection records documenting sterile compounding deficiencies, voluntary product recalls, and a formal FDA warning letter.
Injury claims range from ocular infections and vision loss to systemic infections associated with contaminated injectables.
Who qualifies to file an Empower Pharmacy lawsuit claim in 2026?
A person qualifies if they received a compounded medication from Empower Pharmacy and suffered a documented physical injury that is medically consistent with a contaminated or defective pharmaceutical product.
Qualification requires medical records establishing both the product administration and the resulting harm.
People who received recalled products but experienced no documented injury generally do not have viable claims under current litigation standards.
How much compensation could an Empower Pharmacy lawsuit claim be worth?
Compensation depends on the severity and permanence of the documented injury, with estimates ranging from $25,000 for minor resolved infections to $5 million or more for catastrophic injuries such as permanent vision loss or life-threatening systemic infection.
No global settlement has been announced, so these figures reflect comparable pharmaceutical contamination litigation outcomes.
Punitive damages may apply in cases where the defendant's notice of deficiencies and continued distribution can be proven.
Has Empower Pharmacy reached a settlement in 2026?
No global Empower Pharmacy settlement has been announced as of the publication date of this article.
Individual cases may resolve through private negotiation without public disclosure.
Litigation is in the active discovery phase, and the timeline for a global settlement is consistent with comparable mass tort cases, which typically take 18 to 36 months to reach resolution frameworks.
What is the filing deadline for an Empower Pharmacy lawsuit?
There is no single universal filing deadline. Each state applies its own statute of limitations, typically two to three years from the date of injury or from the date the patient discovered the connection between the product and their harm.
In Texas, where Empower Pharmacy is headquartered, the personal injury statute of limitations is 2 years.
Patients harmed in 2023 or early 2024 may be approaching or within that window and should consult an attorney without delay.
What type of attorney handles Empower Pharmacy lawsuit claims?
These claims are handled by plaintiffs' attorneys specializing in pharmaceutical product liability, mass tort litigation, and personal injury law with specific experience in FDA-regulated manufacturing disputes.
Attorneys in this space work on contingency, meaning no upfront fee is required.
Choosing an attorney with experience in compounding pharmacy litigation specifically is important, given the technical regulatory knowledge these cases require.
Closing
The Empower Pharmacy lawsuit is a legally complex, medically serious, and rapidly developing matter. The regulatory record established by the FDA creates a factual foundation that is stronger than in most pharmaceutical injury cases. Litigation is active, deadlines are real, and case values are substantial for those with documented serious injuries.
If you or a family member received compounded medications from Empower Pharmacy and experienced an infection, vision problem, or other serious medical event, the appropriate step is to consult an attorney who handles pharmaceutical product liability cases. That consultation should happen before statute of limitations windows close, and before physical evidence is lost or records become harder to obtain.
